Kathleen Laporte - Sep 25, 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role: Director
Signature: /s/ Kathleen LaPorte
Stock symbol: CERO
Transactions as of: Sep 25, 2024
Transactions value $: -$50,000
Form type: 4
Date filed: 10/2/2024, 09:53 PM
Previous filing: Sep 6, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERO	Common Stock	Options Exercise		+966K			966K	Sep 25, 2024	By the Kathleen LaPorte Revocable Trust	F1, F2
holding	CERO	Common Stock						5.83K	Sep 25, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERO	Series A Convertible Preferred Stock	Options Exercise	-$50K	-50	-100%	$1,000.00	0	Sep 25, 2024	Common Stock	966K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date.
F2	The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the "Trust") and has sole voting and disposition power with respect to the shares owned by the Trust.

Content

On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date.

The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the "Trust") and has sole voting and disposition power with respect to the shares owned by the Trust.